Mehr lesen
This book aims to provide an updated information on different types of major and emerging drugs for managing liver cirrhosis and its complications, including acute gastroesophageal variceal bleeding, ascites, hepatic encephalopathy, liver failure, acute kidney injury, and portal venous thrombosis. The chapters are organized by drug class, such as anti-HBV drugs, anti-HCV drugs, anticoagulants, and antibiotics, etc. The clinical efficacy, indication, and contra-indication of the various drug therapies are discussed using supportive reference material from authoritative sources and published clinical trials. It will be an invaluable reference for physicians who are treating patients with liver cirrhosis, especially those presenting with acute life-threatening complications.
Inhaltsverzeichnis
Anti-HBV drugs in liver cirrhosis.- Anti-HCV drugs in liver cirrhosis.- Anticoagulants in liver cirrhosis.- Antibiotics in liver cirrhosis.- Silymarin in liver cirrhosis.- Ursodeoxycholic acid in liver cirrhosis.- Emricasan in liver cirrhosis.- Non-selective beta blockers in liver cirrhosis.- Somatostatin and octreotide in liver cirrhosis.- Terlipressin in liver cirrhosis.- Diuretics in liver cirrhosis.- Statins in liver cirrhosis.- L-Ornithine L-Aspartate in liver cirrhosis.- Lactulose in liver cirrhosis.
Über den Autor / die Autorin
Xingshun Qi is an Associate Professor at the Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Yongping Yang is a Professor at Department of Liver Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
